Plasma Glycated CD59 Predicts Early Gestational Diabetes and Large for Gestational Age Newborns

Categories: Basic Science, Infancy, Maternal, Metabolic Health

Tags Insulin Resistance & Diabetes

Type Article

Journal Article

Authors

D. Ma; M. A. Luque-Fernandez; D. Bogdanet; G. Desoye; F. Dunne; J. A. Halperin

Year of publication

2020

Publication/Journal

J Clin Endocrinol Metab

Volume

105

Issue

Pages

e1033-40

Abstract

CONTEXT: Gestational diabetes mellitus (GDM) diagnosed in early pregnancy is a health care challenge because it increases the risk of adverse outcomes. Plasma-glycated CD59 (pGCD59) is an emerging biomarker for diabetes and GDM. The aim of this study was to assess the performance of pGCD59 as a biomarker of early GDM and its association with delivering a large for gestational age (LGA) infant. OBJECTIVES: To assess the performance of pGCD59 to identify women with GDM in early pregnancy (GDM 29) undergoing a 75-g, 2-hour oral glucose tolerance test (OGTT) at